<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01102101</url>
  </required_header>
  <id_info>
    <org_study_id>VHPRG-HighDoseRemiPostHerpetic</org_study_id>
    <nct_id>NCT01102101</nct_id>
  </id_info>
  <brief_title>Effect of Opioids in Neuropathic Pain in Postherpetic Patients</brief_title>
  <acronym>VHPRG-HDRPH</acronym>
  <official_title>Effect of Opioids in Neuropathic Pain in Postherpetic Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Vienna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>WWTF, Wiener Wissenschafts-, Forschungs- und Technologiefonds</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Vienna General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Medical University of Vienna</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Postherpetic neuralgia (PHN) is often associated with pain and sensory changes and is the
      leading type of neuropathic pain in modern clinical pain research. It is characterized by a
      variety of sensory patterns, which may be categorized into &quot;irritable nociceptor&quot; and
      &quot;impairment of nociceptor&quot;. At date, several lines of evidence lead to the assumption, that
      mechanical hyperalgesia in PHN is based - at least in part - on central nervous processes of
      sensitization.

      In animal studies the investigators have discovered a previously unrecognized effect of
      opioids, the reversal of long-term potentiation (LTP) at C-fibre synapses, i.e. an
      opioid-induced depotentiation. In principle, synaptic depotentiation may be permanent or
      transient. In our study the clinically used ultra-short acting MOR agonist remifentanil
      normalized synaptic strength after wash-out of the drug. At present it is not known whether
      opioid-induced depotentiation can be used to the benefit of pain patients.

      The aim is to study the hypothesis, that pain in a group of PHN patients with predominant
      mechanical hyperalgesia is reversed by intravenous remifentanil at a plasma target
      concentration of 18ng/ml (corresponding to about 0.75 µg/kg/min) for 60 minutes compared with
      PHN patients of other sensory types.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>August 2010</start_date>
  <completion_date type="Anticipated">March 2011</completion_date>
  <primary_completion_date type="Anticipated">March 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Stimulus-response (SR)-function</measure>
    <time_frame>7 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pinprick</measure>
    <time_frame>7 days</time_frame>
    <description>Area of secondary hyperalgesia assessed by pinprick</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area of dynamic allodynia</measure>
    <time_frame>7 days</time_frame>
    <description>Brush, Q Tip, Cotton Wool</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NRS</measure>
    <time_frame>7 days</time_frame>
    <description>Pain according to numeric rating scale (NRS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mechanical pain threshold</measure>
    <time_frame>7 days</time_frame>
    <description>Mechanical pain threshold measured with v. Frey Filaments</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HPPT</measure>
    <time_frame>7 days</time_frame>
    <description>Heat pain perception threshold (HPPT) with thermal sensory analyzer (TSA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HPTT</measure>
    <time_frame>7 days</time_frame>
    <description>Heat pain tolerance threshold (HPTT) measured with TSA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Coolness</measure>
    <time_frame>7 days</time_frame>
    <description>Coolness perception threshold measured with TSA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Warmth</measure>
    <time_frame>7 days</time_frame>
    <description>Warmth perception threshold measured with TSA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LDPI</measure>
    <time_frame>7 days</time_frame>
    <description>Laser Doppler Perfusion Imager (LDPI) measuring superficial perfusion of the dermatome</description>
  </secondary_outcome>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Neuralgia, Postherpetic</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Remifentanil</intervention_name>
    <description>Remifentanil (Ultiva; Glaxo-Smith-Kline; Vienna, Austria) will be applied intravenously during 60 minutes through a dedicated infusion pump (TCI Alaris PK Syringe Pump, Cardinal Health, Baesweiler, Germany), with a Target Controlled Infusion (following the integrated software algorithm by Minto), reaching the initial 18ng/ml plasma concentration in 180 seconds. This corresponds to approx. 0.7 µg kg-1 min-1.</description>
    <other_name>Remifentanil (Ultiva; Glaxo-Smith-Kline; Vienna, Austria)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients suffering from PHN.

          -  Pain ≥ 4 out of 10 in numeric rating scale (NRS)

          -  Female and male patients above the age of 18

          -  Ability to understand/write/read german

        Exclusion Criteria:

          -  Zoster affecting trigeminal-, opticus region

          -  Any somatic pain which is stronger than the neuropathic pain

          -  Severe progressive disease

          -  Acute cardiac decompensation

          -  Known cardiac valve dysfunction

          -  Known pulmonary hypertension

          -  Cardiac conduction disturbance

          -  Active herpetic lesion

          -  Opioid therapy

          -  Asthma bronchial

          -  Chronic obstructive pulmonary disease &gt;GOLD II

          -  Severe psychiatric condition

          -  Abuse of alcoholic beverages, drug abuse

          -  Negative neuropathic symptoms

          -  Pregnancy or breast feeding

          -  Participation in a clinical trial in the 2 weeks preceding the study

          -  Allergy against any medication used in the study protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>General Hospital Vienna, Medical University of Vienna</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bernhard Roessler, Dr</last_name>
      <phone>00431404006428</phone>
      <email>bernhard.roessler@meduniwien.ac.at</email>
    </contact>
    <contact_backup>
      <last_name>Burkhard Gustorff, Prof., Dr.</last_name>
      <phone>00431491504001</phone>
      <email>burkhard.gustorff@meduniwien.ac.at</email>
    </contact_backup>
    <investigator>
      <last_name>Bernhard Roessler, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Astrid Chiari, Prof., Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Burkhard Gustroff, Prof., Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Juergen Sandkuehler, Prof., Dr. PHD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ruth Drdla, Dr. PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wilhelminenspital der Stadt WIen</name>
      <address>
        <city>Vienna</city>
        <zip>1160</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Burkhard Gustroff, Prof., Dr.</last_name>
      <phone>00431491504001</phone>
      <email>burkhard.gustroff@meduniwien.ac.at</email>
    </contact>
    <investigator>
      <last_name>Burkhard Gustroff, Prof., Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>April 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 6, 2010</study_first_submitted>
  <study_first_submitted_qc>April 9, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 12, 2010</study_first_posted>
  <last_update_submitted>April 9, 2010</last_update_submitted>
  <last_update_submitted_qc>April 9, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 12, 2010</last_update_posted>
  <responsible_party>
    <name_title>Professor Burkhard Gustorff</name_title>
    <organization>Vienna Human Pain Research Group, Deparmtent of Anaesthesia, Medical University of Vienna</organization>
  </responsible_party>
  <keyword>Remifentanil</keyword>
  <keyword>Hyperalgesia</keyword>
  <keyword>Zoster</keyword>
  <keyword>Postherpetic neuralgia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuralgia</mesh_term>
    <mesh_term>Neuralgia, Postherpetic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Remifentanil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

